Vortioxetine's post-marketing safety profile determined through cluster analysis of global adverse event reports

被引：0
|
作者：
Ekhart, Corine [1 ]
van Hunsel, Florence [1 ]
van Puijenbroek, Eugene [1 ,2 ]
Chandler, Rebecca [3 ]
Meldau, Eva-Lisa [3 ]
Noren, Niklas [3 ]
机构：
[1] Netherlands Pharmacovigilance Ctr Lareb, Shertogenbosch, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Uppsala Monitoring Ctr, Uppsala, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4070
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [21] Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system
    Ding, Yiling
    Su, Hongyan
    Shu, Yamin
    Chen, Jing
    HELIYON, 2024, 10 (09)
  • [22] Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system
    Liu, Fengfen
    Su, Huaiyu
    Wei, Wei
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [23] Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system
    Al-Ahmari, Abdullah K.
    AlAsmari, Amnah
    AlKorbi, Anoud
    Ahmed, Nehad J.
    Almalki, Ziyad S.
    Alshehri, Ahmed M.
    Albassam, Ahmed A.
    Alem, Ghada M.
    SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (08) : 1137 - 1142
  • [24] What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System
    Lunghi, C.
    Fusaroli, M.
    Giunchi, V.
    Raschi, E.
    Zongo, A.
    Poluzzi, E.
    DRUG SAFETY, 2022, 45 (10) : 1242 - 1243
  • [25] Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis
    Li, Jing
    Gong, Junjie
    Liu, Ziyu
    Liu, Yuheng
    He, Anqi
    Wang, Zengguang
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2024,
  • [26] Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database
    Kumar, Nitin
    Kalaiselvan, Vivekanandan
    Arora, Mandeep Kumar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1685 - 1695
  • [27] A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
    Hoffman, Keith B.
    Dimbil, Mo
    Tatonetti, Nicholas P.
    Kyle, Robert F.
    DRUG SAFETY, 2016, 39 (06) : 561 - 575
  • [28] A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
    Keith B. Hoffman
    Mo Dimbil
    Nicholas P. Tatonetti
    Robert F. Kyle
    Drug Safety, 2016, 39 : 561 - 575
  • [29] COMPARISON OF THE POST-MARKETING SAFETY PROFILE BETWEEN INFLUENZA AND COVID-19 VACCINES: AN ANALYSIS OF THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
    Alahmari, A. K.
    Almalki, Z.
    Alshehri, A.
    Albassam, A. A.
    Ahmed, N. J.
    VALUE IN HEALTH, 2022, 25 (07) : S454 - S454
  • [30] Safety of Sublingual Immunotherapy: A Secondary Analysis of Post-marketing Adverse Events Reports Using a Japanese Public Database
    Kaneda, Yudai
    Kaneda, Uiri
    Namba, Mira
    Tanimoto, Tetsuya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
12345